JP2019501224A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501224A5
JP2019501224A5 JP2018554651A JP2018554651A JP2019501224A5 JP 2019501224 A5 JP2019501224 A5 JP 2019501224A5 JP 2018554651 A JP2018554651 A JP 2018554651A JP 2018554651 A JP2018554651 A JP 2018554651A JP 2019501224 A5 JP2019501224 A5 JP 2019501224A5
Authority
JP
Japan
Prior art keywords
carboxylic acid
trifluoromethyl
chromene
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018554651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501224A (ja
JP6942726B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012737 external-priority patent/WO2017120591A1/en
Publication of JP2019501224A publication Critical patent/JP2019501224A/ja
Publication of JP2019501224A5 publication Critical patent/JP2019501224A5/ja
Application granted granted Critical
Publication of JP6942726B2 publication Critical patent/JP6942726B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018554651A 2016-01-08 2017-01-09 クロメン化合物および第2活性薬剤の併用薬 Active JP6942726B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276713P 2016-01-08 2016-01-08
US62/276,713 2016-01-08
US201662277225P 2016-01-11 2016-01-11
US62/277,225 2016-01-11
PCT/US2017/012737 WO2017120591A1 (en) 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent

Publications (3)

Publication Number Publication Date
JP2019501224A JP2019501224A (ja) 2019-01-17
JP2019501224A5 true JP2019501224A5 (OSRAM) 2020-02-13
JP6942726B2 JP6942726B2 (ja) 2021-09-29

Family

ID=59274050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554651A Active JP6942726B2 (ja) 2016-01-08 2017-01-09 クロメン化合物および第2活性薬剤の併用薬

Country Status (9)

Country Link
US (2) US20170196835A1 (OSRAM)
EP (1) EP3400218A4 (OSRAM)
JP (1) JP6942726B2 (OSRAM)
KR (1) KR20180100652A (OSRAM)
CN (1) CN108779091B (OSRAM)
AU (1) AU2017206108B2 (OSRAM)
CA (1) CA3010848A1 (OSRAM)
MX (1) MX388579B (OSRAM)
WO (1) WO2017120591A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220130249A (ko) 2016-05-26 2022-09-26 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
CN110869055B (zh) * 2017-07-20 2023-04-28 国立大学法人北海道大学 靶向pd-1/pd-l1的抑制剂与cox-2抑制剂的组合使用
TR201900059A2 (tr) 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
TWI869398B (zh) * 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
EP4051260A4 (en) * 2019-10-28 2023-12-06 Enzychem Lifesciences Corporation Methods and compositions for treatment of cancer
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
CA3174675A1 (en) 2020-04-29 2021-11-04 Relay Therapeutics, Inc. Pi3k.alpha. inhibitors and methods of use thereof
EP4412606A4 (en) * 2021-10-07 2025-09-24 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
KR102889598B1 (ko) * 2023-02-16 2025-11-21 주식회사 재인알앤피 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20040127470A1 (en) 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP2175722A4 (en) 2007-07-12 2010-08-25 Tragara Pharmaceuticals Inc PATIENT SELECTION AND THERAPEUTIC PROCEDURES WITH PROSTAGLAND INMETABOLISM MARKERS
CN102757417B (zh) 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN103012350B (zh) * 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
CN103044477B (zh) 2012-12-07 2015-08-05 中国科学院广州生物医药与健康研究院 三甲基硅取代苯并吡喃类化合物及其应用
US9452228B2 (en) * 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

Similar Documents

Publication Publication Date Title
JP2019501224A5 (OSRAM)
EP4356973A3 (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
SA520411982B1 (ar) Kirsten 2 مثبطات نظير الجين الورمي الفيروسي لساركوما جرذ (KRas) واستخدامها لعلاج السرطان
JP2016518437A5 (OSRAM)
SG11201907038WA (en) Quinazoline compound
JP2015500887A5 (OSRAM)
MY207716A (en) Hiv inhibitor compounds
JP2017105793A5 (OSRAM)
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
JP2016501221A5 (OSRAM)
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
WO2019035914A8 (en) Macrocyclic mcl-1 inhibitors and methods of use
JP2013542261A5 (OSRAM)
JP2016528301A5 (OSRAM)
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
PH12015501836A1 (en) 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
MY199779A (en) Pyrrolopyrimidine compound and use thereof
JP2019519533A5 (OSRAM)
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2023009388A (es) Metodos para tratar alteraciones del comportamiento.
HK1255438A1 (zh) 用於治疗癌症的(s,e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
MA55084A (fr) Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
EP4591940A3 (en) Deoxy- cytidine derivatives for use in cancer therapies